Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meloxicam + rizatriptan
- Development stage
- Approved
- Lead developer
- Axsome Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Meloxicam + rizatriptan** is an oral fixed-dose combination medicine marketed as **Symbravo** for the acute treatment of migraine with or without aura in adults. It combines MoSEIC meloxicam, a cyclooxygenase inhibitor NSAID formulated to enhance meloxicam absorption, with rizatriptan, a selective serotonin 5-HT1B/5-HT1D receptor agonist. The complementary mechanisms are intended to provide rapid relief of migraine symptoms and sustained control of pain recurrence. The United States product is an immediate-release tablet containing meloxicam 20 mg and rizatriptan 10 mg.
- Brand names
- Symbravo
- Other names
- meloxicam and rizatriptanmeloxicam/rizatriptanmMRMoSEIC meloxicam/rizatriptan
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)
Beyond the preview
Go deeper on meloxicam + rizatriptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meloxicam + rizatriptan.